Search clinical trials for: Tick-Borne Encephalitis vaccine

Total 146 results

Novartis
Novartis Vaccines

Completed

Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children

Encephalitis, Tick-Borne

Germany
Pfizer

Completed

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

Tick-borne Encephalitis

Austria, Germany
Pfizer

Completed

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Tick-borne Encephalitis

Germany
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Encephalitis, Tick-Borne

Germany
Pfizer

Completed

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Encephalitis, Tick-borne

Belgium
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Encephalitis, Tick-borne

Austria, Germany
Pfizer

Completed

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Encephalitis, Tick-borne

Austria
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years

Encephalitis, Tick-borne

Poland
Pfizer

Completed

Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR

Encephalitis, Tick-borne

Poland
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Encephalitis, Tick-Borne

Germany, Austria, Poland
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Encephalitis, Tick-borne

Germany
Pfizer

Completed

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Encephalitis, Tick-Borne

Austria, Czechia
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)

Encephalitis, Tick-Borne

Poland
Dr. med. Micha Loebermann

Completed

Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Germany
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

Influenza, Human

Finland, Italy, Germany
Boryung Pharmaceutical Co., Ltd

Completed

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (BR-JELITE)

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Japanese Encephalitis | Encephalitis

Thailand
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Purified Inactivated Japanese Encephalitis Vaccine

Japanese Encephalitis Virus Disease

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Japanese Encephalitis | Hepatitis A

Thailand, Philippines
Cancer Institute and Hospital, Chinese Academy...
Guangdong Center for Disease Prevention and Control

Unknown

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Hand, Foot and Mouth Disease (HFMD)

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Japanese Encephalitis | Japanese Encephalitis Virus Disease

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Japanese Encephalitis | Hepatitis A

Thailand
Singapore General Hospital
Duke-NUS Graduate Medical School

Completed

The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans

Encephalitis, Japanese | Yellow Fever

Singapore
Jiangsu Province Centers for Disease Control and...
Shandong Hengye Biotech Co., Ltd.

Completed

A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants

Encephalitis

China
Medical University of Vienna

Completed

TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Vaccine Responsiveness in Allergy | Vaccine Responsiveness During Allergy De-sensitization Treatment

Austria
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Novartis
Novartis Vaccines

Completed

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Japanese Encephalitis | Rabies | Yellow Fever | Meningococcal Disease | Typhoid | Meningococcal Meningitis

Czech Republic, Germany
Centers for Disease Control and Prevention, China
Centers for Disease Control and Prevention; Zhejiang Provincial Center for... and other collaborators

Completed

Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines (MR+JE)

Japanese Encephalitis | Measles | Rubella

China
Chulalongkorn University
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Japanese Encephalitis
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Singapore General Hospital
Duke-NUS Graduate Medical School

Recruiting

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Japanese Encephalitis | Infectious Disease | Yellow Fever | Viral Infection

Singapore
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Dengue Fever

Thailand
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Siriraj Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Encephalitis
U.S. Army Medical Research and Development Command

Completed

Western Equine Encephalitis Vaccine, Inactivated (WEE)

Virus

United States
PATH
Mahidol University; Ministry of Health of Sri Lanka; Quintiles Singapore

Completed

Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (JEV03)

Japanese Encephalitis

Sri Lanka
Khon Kaen University

Unknown

Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children

Japanese Encephalitis

Thailand
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Liaoning Chengda Biotechnology CO., LTD

Recruiting

Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

Japanese Encephalitis | Measles | Rubella | Mumps

China
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Japanese Encephalitis
IRCCS Sacro Cuore Don Calabria di Negrar

Recruiting

Insights Into Tick-Borne Diseases: a Study From an Endemic Area of Northern Italy (TICKTOC)

Tick-Borne Diseases

Italy
Novartis Vaccines

Completed

Novartis Vaccine and Diagnostics Carriage Trial

N. Meningitidis Carriage

United Kingdom
U.S. Army Medical Research and Development Command

Unknown

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

Western Equine Encephalitis

United States
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States

3

Subscribe